Curis (CRIS) Enterprise Value (2010 - 2026)
Curis' (CRIS) quarterly Enterprise Value came in at -$15.0 million in Q1 2026, up 26.04% YoY from -$11.9 million in Q1 2025, and down 196.4% on a QoQ basis from -$5.1 million in Q4 2025.
Curis (CRIS) Enterprise Value (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Enterprise Value data on file, last reported at -$15.0 million in Q1 2026.
- Quarterly Enterprise Value rose 26.04% year-over-year to -$15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.0 million (up 26.04% YoY) and the FY2025 annual result came in at -$5.1 million, up 74.69% from the prior year.
- Enterprise Value eased to -$15.0 million in Q1 2026, from -$5.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.1 million in Q4 2025 to a low of -$120.7 million in Q1 2022.
- A 5-year average of -$49.5 million and a median of -$40.7 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value climbed 22.86% — and 2025, when it jumped 74.69%.
- Tracing CRIS's Enterprise Value over 5 years: stood at -$85.6 million in 2022, then surged by 34.21% to -$56.3 million in 2023, then surged by 64.5% to -$20.0 million in 2024, then jumped by 74.69% to -$5.1 million in 2025, then tumbled by 196.4% to -$15.0 million in 2026.
- The last three Enterprise Value figures came in at -$15.0 million (Q1 2026), -$5.1 million (Q4 2025), and -$9.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.00 Mn |
| Dec 31, 2025 | -5.06 Mn |
| Sep 30, 2025 | -9.05 Mn |
| Jun 30, 2025 | -10.14 Mn |
| Mar 31, 2025 | -20.28 Mn |
| Dec 31, 2024 | -20.00 Mn |
| Sep 30, 2024 | -20.85 Mn |
| Jun 30, 2024 | -28.36 Mn |
| Mar 31, 2024 | -40.72 Mn |
| Dec 31, 2023 | -56.33 Mn |
| Sep 30, 2023 | -68.50 Mn |
| Jun 30, 2023 | -63.49 Mn |
| Mar 31, 2023 | -71.76 Mn |
| Dec 31, 2022 | -85.62 Mn |
| Sep 30, 2022 | -98.69 Mn |
| Jun 30, 2022 | -107.20 Mn |
| Mar 31, 2022 | -120.65 Mn |
| Dec 31, 2021 | -115.88 Mn |
| Sep 30, 2021 | -128.90 Mn |
| Jun 30, 2021 | -152.57 Mn |